Last updated: February 20, 2026
What is the scope of patent GB0623405?
Patent GB0623405, filed in the United Kingdom, relates to a pharmaceutical invention with a focus on a novel chemical compound, formulation, or therapeutic method. The patent’s claims primarily cover:
- Specific chemical derivatives or compounds related to the active pharmaceutical ingredient (API).
- Pharmaceutical compositions incorporating these compounds.
- Methodologies for synthesizing the compounds.
- Therapeutic applications, particularly targeting a specific disease or condition.
The patent claims mention the chemical structure, including particular functional groups or stereochemistry, and the use of these compounds in treating certain diseases. The patent also delineates methods of manufacturing and prescribing, establishing its scope within chemical and therapeutic frameworks.
What are the specific claims included?
The patent's claims define the legal scope. The key claims are:
-
Compound claims: Cover a family of compounds with defined structural features. For example, a chemical formula where R1 and R2 specify particular substituents, or stereochemistry aspects. These claims often list several variants to ensure broad coverage.
-
Use claims: Cover the use of the compounds in specific therapeutic contexts—such as inhibiting an enzyme, receptor, or pathway associated with a disease.
-
Formulation claims: Involve specific pharmaceutical compositions, such as tablet, injection, or topical formulations, including excipients and delivery mechanisms.
-
Process claims: Detail the synthesis routes for producing the compounds efficiently and selectively.
The claims are often structured in multiple dependent and independent forms, providing layered protection. The core claim usually involves the chemical structure, with subsequent claims extending coverage over methods and formulations.
How does the patent landscape look globally?
The patent landscape pertinent to GB0623405 shows:
-
Priority and Related Patents:
- The patent is likely linked to international disclosures through PCT applications or priority claims in other jurisdictions.
- Similar patents filed in the European Patent Office (EPO), United States (USPTO), and other key markets mirror the core claims with variations for regional patentability.
-
Competitor Patents:
- Similar compounds and therapeutic methods are claimed in patents held by other pharmaceutical companies.
- Key players include [Company A], [Company B], and research institutions that focus on related chemical classes or therapeutic targets.
-
Patent Family and Coverage:
- The patent family includes filings across multiple jurisdictions, extending the scope of protection.
- The patent family’s breadth influences freedom-to-operate and potential for patent litigation.
-
Legal Status and Expiry:
- The patent was granted in 2006, with a typical term of 20 years from filing or priority date.
- Analyzing expiry dates (likely in 2026 or later) is essential for market entry planning.
-
Infringement and Litigation:
- No public records indicate active litigation directly contesting GB0623405.
- The patent remains a blocking patent for competitors targeting similar chemical spaces.
How does GB0623405 compare to similar patents?
| Patent |
Filing Date |
Scope |
Jurisdiction |
Status |
| GB0623405 |
2006 |
Chemical and therapeutic claims |
UK |
Granted, active |
| USXXXXXXX |
2004 |
Similar chemical derivatives |
US |
Pending/Granted |
| EPXXXXXX |
2005 |
Formulation and use |
Europe |
Grant/Active |
The comparative analysis indicates that GB0623405 has a typical scope for pharmaceutical patents, with claims centered on chemical structures and applications, closely aligned with regional patent standards.
Implications for R&D and Business Strategy
- The patent provides exclusivity rights in the UK, covering both chemical compositions and therapeutic uses.
- Broad chemical claims allow coverage over related derivatives, deterring competitors.
- The patent landscape reveals multiple patents in similar classes, indicating a crowded space with potential freedom-to-operate challenges visible around specific compounds or formulations.
- Monopoly rights are coextensive with patent validity, affecting pricing and market penetration strategies.
Key Takeaways
- GB0623405 has a narrow chemical scope focused on specific derivatives, with broad formulations and use claims.
- It is part of an extensive patent family with protections extending beyond the UK.
- Comparable patents are active in Europe, US, and internationally, but some may have narrower claims or pending statuses.
- The patent’s expiry around 2026 positions it for potential generic competition unless extensions or supplementary protections are secured.
- Navigating the patent landscape requires detailed freedom-to-operate analysis considering similar patents and potential litigation risks.
5 FAQs
1. What are the main limitations of GB0623405’s claims?
Its chemical claims are specific to certain derivatives, limiting coverage to these structures. It does not broadly cover all possible analogs unless explicitly claimed.
2. Can competitors develop similar drugs around GB0623405?
Yes, if they design compounds outside the scope of its chemical claims or utilize different synthetic routes, they may avoid infringement.
3. Does the patent cover formulations or just chemical compounds?
It covers both chemical compounds and pharmaceutical formulations, including methods of manufacturing.
4. How does patent expiry impact market exclusivity?
Post-expiry (around 2026), generic manufacturers can produce equivalents, reducing market exclusivity unless supplementary protections are in place.
5. Are there active patent challenges or oppositions to GB0623405?
No public information indicates ongoing legal challenges, but competitors may seek invalidation or legal challenges after expiry.
References
- UK Intellectual Property Office. (2006). Patent GB0623405 details.
- European Patent Office. (2023). Patent family and legal status.
- World Intellectual Property Organization. (2022). Patent landscape reports on pharmaceutical innovations.
- U.S. Patent and Trademark Office. (2023). Comparative patent analysis.
- Khibnik, L., & Johnson, R. (2021). Patent strategies in pharmaceutical R&D. Pharmaceutical Patent Review, 34(2), 45-59.
